Αποτελέσματα Αναζήτησης
25 Μαΐ 2020 · We wanted to compare the efficacy and safety of the anthracycline regimen EC-TH versus nonanthracycline regimen TCH in neoadjuvant setting for HER2-positive breast cancer.
Treatment overview. This treatment regimen consists of two parts: 4 cycles of AC, followed by 4 cycles of TH and 13 cycles of trastuzumab. Breast neoadjuvant/adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly. Breast adjuvant TH (DOCEtaxel and trastuzumab) three weekly.
13 Σεπ 2019 · With a median follow up of 65 months, 5-year DFS was superior in trastuzumab-containing arms: 81% (p = 0.04) in the TCH arm, 84% (p < 0.001) in the AC-TH arm, and 75% in the AC-T arm...
1 Μαΐ 2018 · Dose-Dense AC + TH is often given with the goal of cure and administered either before surgery (neoadjuvant therapy) to shrink the size of the tumor, or after surgery (adjuvant therapy) to kill any cancer cells that may be still present in the body.
Results: In this study (N = 121), pCR was numerically higher with pertuzumab based regimens, including ddAC-THP (60%), TCHP (63%), THP (55%), as compared with ddAC-TH (46%). THP resulted in significantly less cycle delays due to toxicity compared to the other regimens (p=0.02).
12 Μαρ 2024 · Patients with tumors larger than 2 cm should be considered for HP-based neoadjuvant therapy regardless of lymph node status. Although TCHP is considered the preferred regimen by NCCN guidelines, we believe weekly paclitaxel is an acceptable option on the basis of available safety and efficacy data. The role of carboplatin remains not well defined.
26 Απρ 2016 · Less cardiotoxicity is seen with TCH (docetaxel, carboplatin, and trastuzumab) than with AC→TH (doxorubicin and cyclophosphamide→docetaxel and trastuzumab), and TCH is recommended for patients at higher risk for cardiotoxicity.*
